These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31113613)

  • 1. Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis?
    Gravito-Soares M; Gravito-Soares E; Gomes D; Tome L
    Ann Hepatol; 2019; 18(1):78-88. PubMed ID: 31113613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.
    Angelico F; Corradini SG; Pastori D; Fargion S; Fracanzani AL; Angelico M; Bolondi L; Tozzi G; Pujatti PL; Labbadia G; Corazza GR; Averna M; Perticone F; Croce G; Persico M; Bucci T; Baratta F; Polimeni L; Del Ben M; Violi F;
    Atherosclerosis; 2017 Jul; 262():179-184. PubMed ID: 28396038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease.
    Baratta F; Pastori D; Tozzi G; D'Erasmo L; Di Costanzo A; Arca M; Ettorre E; Ginanni Corradini S; Violi F; Angelico F; Del Ben M
    Liver Int; 2019 Dec; 39(12):2301-2308. PubMed ID: 31392821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?
    Baratta F; Pastori D; Ferro D; Carluccio G; Tozzi G; Angelico F; Violi F; Del Ben M
    World J Gastroenterol; 2019 Aug; 25(30):4172-4180. PubMed ID: 31435171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Frequency of Lysosomal Acid Lipase Deficiency in Children With Unexplained Liver Disease.
    Kuloglu Z; Kansu A; Selbuz S; Kalaycı AG; Şahin G; Kirsaclioglu CT; Demirören K; Dalgıç B; Kasırga E; Önal Z; İşlek A;
    J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):371-376. PubMed ID: 30540705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.
    Selvakumar PK; Kabbany MN; Lopez R; Tozzi G; Alisi A; Alkhouri N; Nobili V
    Dig Liver Dis; 2016 Aug; 48(8):909-13. PubMed ID: 27198736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease.
    Shteyer E; Villenchik R; Mahamid M; Nator N; Safadi R
    Int J Mol Sci; 2016 Feb; 17(3):312. PubMed ID: 26927097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?
    Köse E; Çağatay E; Yaraş T; Kısa PT; Güler S; Gülten ZA; Akarsu M; Oktay Y; Kayalı HA; Arslan N
    Turk J Med Sci; 2022 Aug; 52(4):1075-1084. PubMed ID: 36326406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease.
    Ferri F; Mischitelli M; Tozzi G; Messina E; Mignini I; Mazzuca S; Pellone M; Parisse S; Marrapodi R; Visentini M; Baratta F; Del Ben M; Pastori D; Perciballi R; Attilia ML; Carbone M; De Santis A; Violi F; Angelico F; Ginanni Corradini S
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00116. PubMed ID: 32463622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinical characterization of a series of patients with childhood-onset lysosomal acid lipase deficiency. Retrospective investigations, follow-up and detection of two novel LIPA pathogenic variants.
    Pisciotta L; Tozzi G; Travaglini L; Taurisano R; Lucchi T; Indolfi G; Papadia F; Di Rocco M; D'Antiga L; Crock P; Vora K; Nightingale S; Michelakakis H; Garoufi A; Lykopoulou L; Bertolini S; Calandra S
    Atherosclerosis; 2017 Oct; 265():124-132. PubMed ID: 28881270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C.
    Abdelsameea E; Alsebaey A; Abdel-Razek W; Ehsan N; Morad W; Salama M; Waked I
    Eur J Gastroenterol Hepatol; 2020 Dec; 32(12):1553-1558. PubMed ID: 31972660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.
    Polimeni L; Pastori D; Baratta F; Tozzi G; Novo M; Vicinanza R; Troisi G; Pannitteri G; Ceci F; Scardella L; Violi F; Angelico F; Del Ben M
    Intern Emerg Med; 2017 Dec; 12(8):1159-1165. PubMed ID: 28900817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
    Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
    J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions.
    Bashir A; Duseja A; Verma A; De A; Tiwari P
    J Clin Exp Hepatol; 2022; 12(6):1535-1546. PubMed ID: 36340307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.
    Maciejko JJ
    Am J Cardiovasc Drugs; 2017 Jun; 17(3):217-231. PubMed ID: 28197978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients.
    Omran D; Zayed RA; Nabeel MM; Mobarak L; Zakaria Z; Farid A; Hassany M; Saif S; Mostafa M; Saad OK; Yosry A
    Viral Immunol; 2018 May; 31(4):315-320. PubMed ID: 29630460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology.
    Vespasiani-Gentilucci U; Gallo P; Piemonte F; Riva E; Porcari A; Vorini F; Tozzi G; Piccioni L; Galati G; De Vincentis A; Carotti S; Morini S; D'Amico J; Angeletti S; Pedone C; Picardi A
    PLoS One; 2016; 11(5):e0156113. PubMed ID: 27219619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.